Human medicines European public assessment report (EPAR): Kengrexal, cangrelor, Date of authorisation: 23/03/2015, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Tecentriq, atezolizumab, Date of authorisation: 20/09/2017, Revision: 34, Status: Authorised

Marketing authorisation application (MAA) - pre-submission interactions form

Human medicines European public assessment report (EPAR): Ayvakyt, avapritinib, Date of authorisation: 24/09/2020, Revision: 10, Status: Authorised

CHMP-CAT - D80-210 Overview to final EPAR - Rev 07.25 Revamp

Human medicines European public assessment report (EPAR): Riximyo, rituximab, Date of authorisation: 15/06/2017, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Omnitrope, somatropin, Date of authorisation: 12/04/2006, Revision: 23, Status: Authorised

Human medicines European public assessment report (EPAR): Emtricitabine / Tenofovir alafenamide Viatris, emtricitabine,tenofovir alafenamide, Date of authorisation: 18/07/2025, Status: Authorised

Human medicines European public assessment report (EPAR): Livtencity, maribavir, Date of authorisation: 09/11/2022, Revision: 6, Status: Authorised

PSUSA/00002013/202412